Suzhou Homesun Pharmaceutical

Suzhou Homesun Pharmaceutical is the primary innovative drug research and development subsidiary of Tianjin Chase Sun Pharmaceutical, located in the Suzhou Industrial Park. The company focuses on the discovery and clinical development of small molecule therapeutics, with a strategic emphasis on oncology, critical care, and urology. Its lead internal candidate, KB707, is a potent Toll-like receptor 7 (TLR7) agonist currently being evaluated in clinical trials for the treatment of advanced solid tumors. Additionally, the company supports the development and life-cycle management of the parent group's commercial portfolio, including treatments for overactive bladder and hypertension. Suzhou Homesun integrates advanced medicinal chemistry and pharmacology to bridge the gap between early-stage discovery and large-scale commercialization within the Chase Sun ecosystem.